Tumor subtypes are currently identified by biomarker (such as HER2+ or HER2- breast cancers) or signature gene expression, or signaling pathway activity (such as Sonic Hedgehog (SHH) or Wnt pathways in medulloblastoma) within a small biopsy or region of a resected tumor. Here, ERBB2 is linked to neoplasm.